Portfolio company
Egle Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Regcell
This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.
Dualyx
This company develops immune-modulating therapies targeting regulatory T cells to treat patients with autoimmune diseases.
Epana Bio
This company develops precision T-cell engagers and biologics using artificial intelligence and genomics to treat patients with autoimmune diseases.
SEITO Biologics AG
This biotechnology company develops selective regulatory T cell engagers to treat patients suffering from autoimmune diseases, chronic inflammation and organ transplant rejection.
Ouro Medicines
This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.
Beeline Medicines
This clinical-stage biotechnology company develops precision therapies for patients living with autoimmune and inflammatory diseases.
Abata Therapeutics
This company develops regulatory T cell therapies to treat patients with severe autoimmune and inflammatory diseases including progressive multiple sclerosis and type 1 diabetes.
TRexBio
This biotechnology company develops immunoregulatory medicines for patients with autoimmune and inflammatory diseases by decoding regulatory T cell function in human tissues.